KNOTBODY
Live / Allowed — Published for opposition (as of 03 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 23 Jun 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 79430782
- Mark type
- Stylized text
- Filed
- 23 Jun 2025
- Published for opposition
- 03 Mar 2026
- Attorney of record
- Ben Natter
Goods and services
- Class 001 — Chemicals: Chemicals for use in industry and science; biochemicals, namely, polypeptides and engineered antibodies for scientific, laboratory or research purposes; polypeptides and engineered antibodies for use in the manufacture of pharmaceuticals and drugs; ion channel modulating or G-protein-coupled receptor modulating engineered antibodies, including antagonists or agonists for scientific, laboratory or research purposes; ion channel modulating or G-protein-coupled receptor modulating engineered antibodies, including antagonists or agonists for use in the manufacture of pharmaceuticals and drugs; engineered antibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) for scientific, laboratory or research purposes; engineered antibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) for use in the manufacture of pharmaceuticals and drugs; engineered antibodies derived from mini-protein toxins for scientific, laboratory or research purposes; engineered antibodies derived from mini-protein toxins for use in the manufacture of pharmaceuticals and drugs
- Class 005 — Pharmaceuticals: Pharmaceuticals and pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activity, including preparations for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; drugs for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activity, including preparations for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; engineered antibodies for medical use; pharmaceuticals, drugs and pharmaceutical preparations incorporating engineered antibodies, ion channel modulating engineered antibodies including antagonists or agonists, engineered antibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) or engineered antibodies derived from mini-protein toxins for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activity, including those for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; vaccines
- Class 042 — Scientific and technological services: Scientific and technological services namely scientific research, analysis and testing in the fields of pharmaceuticals, biochemicals, polypeptides, antibodies, ion channel modulating or G-protein-coupled receptor modulating antibodies and antibodies derived from mini-protein toxins; drug discovery and drug development services; conducting or providing research and development services for others in the field of antibodies; scientific and medical research laboratory services relating to the production of antibodies, ion channel modulating antibodies including antagonists or agonists, antibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) or antibodies derived from mini-protein toxins; antibody engineering; scientific research services relating to the discovery, preclinical and clinical development of therapeutic products; information, advisory and consultancy services in relation to all of the aforesaid
- Class 044 — Medical, beauty and agricultural services: Medical services; medical testing, analysis and diagnostic services in the field of antibodies; medical services connected with the treatment of diseases through the use of antibodies, ion channel modulating antibodies including antagonists or agonists, antibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) or antibodies derived from mini-protein toxins, or pharmaceuticals, drugs and pharmaceutical preparations derived from the aforesaid; information, advisory and consultancy services in relation to all of the aforesaid
Owner
Prosecution history
- 03 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Mar 2026 — PUBLISHED FOR OPPOSITION
- 25 Feb 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 07 Feb 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 05 Feb 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 05 Feb 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 05 Feb 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 01 Jan 2026 — REFUSAL PROCESSED BY IB
- 18 Dec 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 18 Dec 2025 — REFUSAL PROCESSED BY MPU
- 12 Nov 2025 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 11 Nov 2025 — NON-FINAL ACTION WRITTEN
- 10 Nov 2025 — ASSIGNED TO EXAMINER
- 25 Aug 2025 — APPLICATION FILING RECEIPT MAILED
- 25 Aug 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED